| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David R P Gua. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. vol 26. issue 8. 2014-03-17. PMID:21840821. |
in vivo in humans, lurasidone has been effective in significantly improving the positive and negative symptoms of schizophrenia in young adults as well as demonstrating preliminary positive effects on cognition in this population. |
2014-03-17 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Mariam Hassan, Ken O'Day, Kellie Meyer, Fred Grossma. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23701260. |
cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. |
2014-03-03 |
2023-08-12 |
Not clear |
| Krithika Rajagopalan, Mariam Hassan, Ken O'Day, Kellie Meyer, Fred Grossma. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics. vol 16. issue 7. 2014-03-03. PMID:23701260. |
compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the us who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. |
2014-03-03 |
2023-08-12 |
Not clear |
| Michael A Miller, Michael Menowsk. Human intravenous injection of β-cyfluthrin with minimal toxic effects. The American journal of emergency medicine. vol 32. issue 1. 2014-02-14. PMID:24079987. |
he was taking oxcarbazepine, lurasidone, and venlafaxine for reported bipolar affective disorder and schizophrenia. |
2014-02-14 |
2023-08-12 |
human |
| Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M Kan. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophrenia research. vol 147. issue 1. 2013-12-09. PMID:23583011. |
effectiveness of lurasidone vs. quetiapine xr for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. |
2013-12-09 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Jane Xu, Kaushik Sarma, Andrei Pikalov, John M Kan. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophrenia research. vol 147. issue 1. 2013-12-09. PMID:23583011. |
to evaluate the relapse prevention efficacy of lurasidone compared with quetiapine xr (qxr) in adults patients with schizophrenia. |
2013-12-09 |
2023-08-12 |
Not clear |
| Oleg V Tcheremissine, Danielle Engler. A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidone. Innovations in clinical neuroscience. vol 10. issue 9-10. 2013-12-05. PMID:24307974. |
a case of paranoid schizophrenia and severe antipsychotic-induced parkinson's disorder treated with a combination of olanzapine and lurasidone. |
2013-12-05 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone in schizophrenia: new information about dosage and place in therapy. Advances in therapy. vol 29. issue 10. 2013-11-12. PMID:23001538. |
lurasidone in schizophrenia: new information about dosage and place in therapy. |
2013-11-12 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone in schizophrenia: new information about dosage and place in therapy. Advances in therapy. vol 29. issue 10. 2013-11-12. PMID:23001538. |
lurasidone is a newer "atypical" or "secondgeneration" antipsychotic that has received regulatory approval in the us and canada for the treatment of schizophrenia. |
2013-11-12 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone in schizophrenia: new information about dosage and place in therapy. Advances in therapy. vol 29. issue 10. 2013-11-12. PMID:23001538. |
additional short-term studies in patients with schizophrenia include a 3-week, randomized, double-blind trial comparing lurasidone with ziprasidone on safety and tolerability outcomes, and a 6-week, randomized, open-label switch study. |
2013-11-12 |
2023-08-12 |
Not clear |
| Leslie Citrom. Lurasidone in schizophrenia: new information about dosage and place in therapy. Advances in therapy. vol 29. issue 10. 2013-11-12. PMID:23001538. |
additional clinical trials are underway for the use of lurasidone in patients with bipolar disorder, including major depressive episodes in patients with bipolar i disorder, and in bipolar and schizophrenia maintenance. |
2013-11-12 |
2023-08-12 |
Not clear |
| Takeshi Murai, Tomokazu Nakako, Masaru Ikejiri, Takeo Ishiyama, Mutsuo Taiji, Kazuhito Iked. Effects of lurasidone on executive function in common marmosets. Behavioural brain research. vol 246. 2013-10-28. PMID:23454675. |
these findings suggest that lurasidone would be more useful for treatment of schizophrenia cognitive impairment than other antipsychotics. |
2013-10-28 |
2023-08-12 |
Not clear |
| Tomoko Horisawa, Hiroyuki Nishikawa, Satoko Toma, Atsushi Ikeda, Masakuni Horiguchi, Michiko Ono, Takeo Ishiyama, Mutsuo Taij. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behavioural brain research. vol 244. 2013-09-30. PMID:23376699. |
taken together, these results suggest that the 5-ht7 receptor antagonistic activity of lurasidone plays an important role in its effectiveness against mk-801-induced deficits, and may contribute to its pharmacological actions in patients with schizophrenia. |
2013-09-30 |
2023-08-12 |
rat |
| Antony Loebel, Josephine Cucchiaro, Kaushik Sarma, Lei Xu, Chuanchieh Hsu, Amir H Kalali, Andrei Pikalov, Steven G Potki. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophrenia research. vol 145. issue 1-3. 2013-09-10. PMID:23415311. |
efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. |
2013-09-10 |
2023-08-12 |
Not clear |
| Antony Loebel, Josephine Cucchiaro, Kaushik Sarma, Lei Xu, Chuanchieh Hsu, Amir H Kalali, Andrei Pikalov, Steven G Potki. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophrenia research. vol 145. issue 1-3. 2013-09-10. PMID:23415311. |
this study was designed to evaluate the short-term efficacy and safety of once-daily lurasidone (80 mg/day and 160 mg/day) in the treatment of an acute exacerbation of schizophrenia. |
2013-09-10 |
2023-08-12 |
Not clear |
| Henry A Nasrallah, Robert Silva, Debra Phillips, Josephine Cucchiaro, Jay Hsu, Jane Xu, Antony Loebe. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. Journal of psychiatric research. vol 47. issue 5. 2013-09-10. PMID:23421963. |
lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. |
2013-09-10 |
2023-08-12 |
Not clear |
| Henry A Nasrallah, Robert Silva, Debra Phillips, Josephine Cucchiaro, Jay Hsu, Jane Xu, Antony Loebe. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. Journal of psychiatric research. vol 47. issue 5. 2013-09-10. PMID:23421963. |
the present study evaluated the efficacy, safety, and tolerability of treatment with the atypical antipsychotic lurasidone for patients with an acute exacerbation of schizophrenia. |
2013-09-10 |
2023-08-12 |
Not clear |
| Henry A Nasrallah, Robert Silva, Debra Phillips, Josephine Cucchiaro, Jay Hsu, Jane Xu, Antony Loebe. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. Journal of psychiatric research. vol 47. issue 5. 2013-09-10. PMID:23421963. |
in this study, in which a large placebo response was observed, lurasidone 80 mg/day, but not 40 mg/day or 120 mg/day, was statistically superior to placebo in treating acute exacerbation of chronic schizophrenia. |
2013-09-10 |
2023-08-12 |
Not clear |
| Stephen M Stahl, Josephine Cucchiaro, Doreen Simonelli, Jay Hsu, Andrei Pikalov, Antony Loebe. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. The Journal of clinical psychiatry. vol 74. issue 5. 2013-08-15. PMID:23541189. |
effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. |
2013-08-15 |
2023-08-12 |
Not clear |
| Stephen M Stahl, Josephine Cucchiaro, Doreen Simonelli, Jay Hsu, Andrei Pikalov, Antony Loebe. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. The Journal of clinical psychiatry. vol 74. issue 5. 2013-08-15. PMID:23541189. |
the primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (dsm-iv). |
2013-08-15 |
2023-08-12 |
Not clear |